Adverse events related to olanzapine

Robert R. Conley*, Herbert Y. Meltzer

*Corresponding author for this work

Research output: Contribution to journalReview article

69 Citations (Scopus)

Abstract

Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment- emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics. Compared with traditional agents, olanzapine shows only a few adverse events such as dry mouth, sedation, and increase in appetite. Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia. Transient, non- dose-dependent, asymptomatic elevations in liver enzymes have also been noted in olanzapine-treated patients. Because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics, consideration should be given to using the newer agents as preferred treatment for schizophrenia and related psychoses.

Original languageEnglish (US)
Pages (from-to)26-30
Number of pages5
JournalJournal of Clinical Psychiatry
Volume61
Issue numberSUPPL. 8
StatePublished - May 22 2000

Fingerprint

olanzapine
Antipsychotic Agents
Schizophrenia
Psychomotor Agitation
Serotonin Antagonists
Hyperprolactinemia
Risperidone
Dopamine Antagonists
Appetite
Psychotic Disorders
Weight Gain
Mouth
Body Mass Index
Liver
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Conley, Robert R. ; Meltzer, Herbert Y. / Adverse events related to olanzapine. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. SUPPL. 8. pp. 26-30.
@article{0d4d9866cc2142e3a384d550b23e0425,
title = "Adverse events related to olanzapine",
abstract = "Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment- emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics. Compared with traditional agents, olanzapine shows only a few adverse events such as dry mouth, sedation, and increase in appetite. Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia. Transient, non- dose-dependent, asymptomatic elevations in liver enzymes have also been noted in olanzapine-treated patients. Because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics, consideration should be given to using the newer agents as preferred treatment for schizophrenia and related psychoses.",
author = "Conley, {Robert R.} and Meltzer, {Herbert Y.}",
year = "2000",
month = "5",
day = "22",
language = "English (US)",
volume = "61",
pages = "26--30",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 8",

}

Conley, RR & Meltzer, HY 2000, 'Adverse events related to olanzapine', Journal of Clinical Psychiatry, vol. 61, no. SUPPL. 8, pp. 26-30.

Adverse events related to olanzapine. / Conley, Robert R.; Meltzer, Herbert Y.

In: Journal of Clinical Psychiatry, Vol. 61, No. SUPPL. 8, 22.05.2000, p. 26-30.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adverse events related to olanzapine

AU - Conley, Robert R.

AU - Meltzer, Herbert Y.

PY - 2000/5/22

Y1 - 2000/5/22

N2 - Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment- emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics. Compared with traditional agents, olanzapine shows only a few adverse events such as dry mouth, sedation, and increase in appetite. Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia. Transient, non- dose-dependent, asymptomatic elevations in liver enzymes have also been noted in olanzapine-treated patients. Because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics, consideration should be given to using the newer agents as preferred treatment for schizophrenia and related psychoses.

AB - Olanzapine, a serotonin-dopamine receptor antagonist, is one of the novel atypical antipsychotics that is effective against the positive and negative symptoms of schizophrenia with significantly fewer treatment- emergent extrapyramidal symptoms and less akathisia associated with traditional antipsychotics. Compared with traditional agents, olanzapine shows only a few adverse events such as dry mouth, sedation, and increase in appetite. Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia. Transient, non- dose-dependent, asymptomatic elevations in liver enzymes have also been noted in olanzapine-treated patients. Because of the comparative efficacy and improved side effect profiles of the atypical antipsychotics, consideration should be given to using the newer agents as preferred treatment for schizophrenia and related psychoses.

UR - http://www.scopus.com/inward/record.url?scp=0034122725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034122725&partnerID=8YFLogxK

M3 - Review article

C2 - 10811240

AN - SCOPUS:0034122725

VL - 61

SP - 26

EP - 30

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 8

ER -